Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Stocks on the Rise.
- M2 PRESSWIRE-17 June 2005-WallStreetGrapevine: Stocks on the RiseC1994-2005 M2 COMMUNICATIONS LTD RDATE:17062005 Wall Street, NYC - Today, wallstreetgrapevine.com, named; FacePrint Global Solutions Inc. (OTC BB: FCPG), Vicuron Pharmaceuticals Inc. (Nasdaq NM: MICU), Immunicon Corporation (Nasdaq NM: IMMC), and Amylin Pharmaceuticals...
- Research articles 2005-06-17
- Behind the Byetta Crisis: Is This Drug Really All That and a Bag of (Fat-Free) Chips?
- The current big headache for Eli Lilly and Amylin is their diabetes drug Byetta, which the FDA has linked to six cases of fatal pancreatitis. The two companies, which jointly market the drug, held a conference call yesterday in which they hoped to calm nervous investors. (It...
- Blog posts 2008-08-28
- Icahn Bruising For Proxy Battle With Amylin Management
- [caption id="attachment_248" align="alignleft" width="200" caption="Byetta"][/caption] Activist investor Carl Icahn announced in a regulatory filing with the Securities and Exchange Commission his intention to nominate a slate of five directors to the board of Amylin Pharmaceuticals at the drugmaker’s May 2009 annual...
- Blog posts 2009-01-29
- Amylin Insists Byetta Doesn't Cause Cancer; Wall Street Doesn't Seem So Sure
- Amylin CEO Daniel Bradbury may be wishing that Novo Nordisk's failed competitor to its diabetes drug Byetta had actually been approved by the FDA. Had Novo's liraglutide passed muster, no one would have gotten the jitters over whether Byetta gives you cancer or not. At Amylin's conference...
- Blog posts 2009-04-21
Additional Resources
- Amylin: A Discounted Option on Byetta's Outcome
- Vincent Fernando submits: Amylin AMLN presents a stock opportunity with substantial optionality, and is currently in the sights of activist investor Carl Icahn. I believe Mr. Icahn may not only be trying to make himself a profit, but may also be trying to get Eli Lilly LLY a good...
- External links 2009-04-22
- The ABCs of Lilly: Amylin, Byetta & Carl
- Mike Huckman submits: Shortly after Eli Lilly LLY reported way better than expected earnings yesterday morning, Amylin Pharmaceuticals AMLN fired a new salvo in its escalating proxy battle with billionaire activist investor Carl Icahn. LLY and AMLN are partners on the twice-a-day injectable diabetes drug Byetta, and...
- External links 2009-04-21
- Amylin v. Icahn Slideshow Battle: Tear Up Lilly-Byetta Agreement!
- Carl Icahn's shareholder presentation in the fight for control of Amylin's board of directors says that the company's joint venture with Eli Lilly on diabetes drug Byetta should be torn up and renegotiated. by Jim Edwards
- Blog posts 2009-05-07
- Amylin May Abandon the "Byetta" Name for Exenatide Once Weekly
- The launch of exenatide once weekly is crucial to Amylin but the company has not yet made a decision on whether it will extend the "Byetta" brand name to the new drug. by Jim Edwards
- Blog posts 2009-05-11
- Eli Lilly Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions And our first question comes from the line of James Kelly of Goldman Sachs. Please go ahead. James Kelly - Goldman Sachs Thank you and good morning. My question relates to Zyprexa and the depot formulation, and thank you for the additional data in Canada...
- Earnings calls 2007-07-24
- Icahn Moves on Amylin; Will Lilly Step Up?
- BNET's 10-Q Detective, David Phillips, reports that Carl Icahn has filed papers to nominate a slate of directors for the board of Amylin, maker of diabetes drug Byetta. The last time Icahn interfered with a smaller company, ImClone, it ended up being bought by Eli Lilly. Here's...
- Blog posts 2009-01-30
- Amylin Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
- Question-and-Answer Session[Operator Instructions]. Your first question comes from the line of CoryKasimov with JPMorgan. Please proceed with your question. CoryKasimov - JPMorgan Great. Good afternoon thanks for taking the question. First of all on exenatide once-weekly and regulatory situation there. What exactly would you need to demonstrate, approve to...
- Earnings calls 2008-01-28
- Why I'm Buying Amylin Now
- Trader Mark submits: I'm following the "buy the busted stocks" instead of breakouts methodology, but breaking a rule on buying individual biotech stocks with today's purchase of Amylin Pharmaceuticals AMLN. This is one of the few biotechs I know pretty well, and have followed for quite a while - mostly...
- External links 2008-08-20
- Amylin Q1: "Icahn Doesn't Know Who Our CEO Is"
- Amylin filed a sarcastic letter describing phone conversations it had with angry investor Carl Ichan over the past few days. "Sarcastic," because the final point in the letter which you can read here is this: Finally, on our call you asked, "Who is Dan Bradbury?" Dan Bradbury is Amylin’s...
- Blog posts 2009-04-20
- Amylin Pharmaceuticals Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Instruction. And your first question comes from the line of Jim Birchenough with Lehman Brothers. Please proceed sir. Jim Birchenough - Lehman Brothers Hi, guys couple of quick questions. Just want to make sure I understand the agreement with FDA on BYETTA LAR regulatory status....
- Earnings calls 2007-07-23
- Inside Amylin's Anti-Icahn Suicide Pact
- Amylin has adopted a financial suicide pact which, in the company's own words, may bankrupt the company if dissident investors Carl Icahn and Eastbourne Capital get a majority of directors elected at the May 27 shareholder meeting. The pact is described in a lawsuit brought by a...
- Blog posts 2009-04-01
- Eli Lilly and Company Q1 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions Your first question comes from the line of Catherine Arnold - Credit Suisse Catherine Arnold - Credit Suisse I was wondering if you could give us an update on the Byetta LAR filing, post [prasugrel] type panel. If you could about...
- Earnings calls 2009-04-20
- Amylin Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions And our first question comes from the line of Salveen Kochnover with Collins Stewart. Please proceed. Daniel Bradbury Hello Salveen. Brent Kelly – Collins Stewart Hello. Hi, this is – sorry this is Brent Kelly in for Salveen. Can you just update us on where...
- Earnings calls 2009-07-22
- Amylin, Lilly: Another Case of a Panic Driven Sell-Off
- A. Reza Saadat submits: On Tuesday August 26, Amylin AMLN and its partner Eli Lilly LLY announced that four patients had died while on diabetes treatment Byetta.Both Amylin (down 12%) and Lilly (down 1%) sold off in after hours following repeated headlines saying Byetta was responsible for the...
- External links 2008-08-27
- Amylin Pharmaceuticals, Inc Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Thomas Wei with Piper Jaffray. Please proceed. Thomas Wei - Piper Jaffray Hi, thanks very much. I wanted to ask about the discussions with the agency on the new label. I guess, how important is the...
- Earnings calls 2009-01-27
- Amylin Battle Heats Up as Eastbourne Capital Touts Rival Directors' Slate to Icahn's
- Eastbourne Capital has proposed a five-member team of its own for Amylin's board. Carl Icahn proposed his own slate last week. Both sets of investors are unhappy with the company that has a joint venture with Eli Lilly on diabetes drug Byetta. Eastbourne said of its move:...
- Blog posts 2009-02-02
- << Previous
- page 1 of 1
- Next >>
